Skip to main content
. Author manuscript; available in PMC: 2007 Feb 10.
Published in final edited form as: Mutat Res. 2006 Oct 23;626(1-2):111–119. doi: 10.1016/j.mrgentox.2006.09.003

Figure 2.

Figure 2

Percent CD71-positive micronucleated reticulocytes (MNCD71+) and percent CD71-positive reticulocytes (ReticCD71+) are graphed for each cancer therapy patient. Treatment details are shown inTable 1. While the frequency of ReticCD71+ was generally found to decline over the first week of treatment, higher incidences of MNCD71+ were observed.